The Complex Connection between Cannabis and Schizophrenia provides an in-depth overview of the current state of research into the role that cannabis plays in schizophrenia, covering both the pathophysiological and the pharmacological implications. It addresses the epidemiology of cannabis use and the risks associated with its use, the biological aspects of the drug, its effects on the brain and the pharmacological possibilities of using cannabidiol to treat schizophrenia. It is the only book on the market devoted exclusively to examining the links between this very commonly used (and misused) drug and a specific set of devastating psychiatric illnesses, providing a comprehensive guide to our current understandings of this relationship. Marijuana is the most commonly used illicit drug globally, and is becoming increasingly decriminalized and even legalized worldwide. Among the numerous mental-health concerns related to the drug, there is mounting evidence of an intricate link between cannabis use and schizophrenia and related psychotic disorders. At the same time, there is promising evidence to suggest that cannabidiol, one of the many compounds found in cannabis that activates the brain’s cannabinoid receptors, could prove to be an effective antipsychotic to treat schizophrenia. Synthesizes existing knowledge about the confusing, but crucial, relationship between cannabis use and schizophrenia symptoms Provides a comprehensive overview of the neurobiological mechanisms of cannabis use and its effects on the brain, including an exploration of the endocannabinoid system Examines the promising evidence suggesting cannabidiol as an effective antipsychotic treatment for schizophrenia Aids readers studying the neurobiological underpinning of cannabis addiction and psychosis in determining directions for their own future research

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.

This book provides a comprehensive overview of the psychiatry and neuroscience of Cannabis sativa (marijuana), with particular emphasis on psychotic disorders. It outlines developments in our understanding of the human cannabinoid system, and links this knowledge to clinical and epidemiological facts about the impact of cannabis on mental health. Clinically focused chapters review not only the direct psychomimetic properties of cannabis, but also the impact consumption has on the courses of evolving or established mental illness such as schizophrenia. A number of controversial issues are critically explored, including whether a discrete 'cannabis psychosis' exists, and whether cannabis can actually cause schizophrenia. Effects of cannabis on mood, notably depression, are reviewed, as are its effects on cognition. This book will be of interest to all members of the mental health team, as well as to neuroscientists and those involved in drug and alcohol research.

With relatable clinical vignettes that illustrate the applicability of each chapter’s content, as well as key chapter points that summarize major themes, Marijuana and Mental Health is the definitive, single source of comprehensive information on marijuana and mental health in modern American society. Balanced, focused, and highly readable, chapters address topics such as the effects of marijuana on the brain and mind, marijuana-related policy and legislation, the complex link between marijuana use and psychotic disorders, synthetic cannabinoids, and the treatment and prevention of marijuana misuse. Beyond offering clinical and research psychiatrists, psychiatric residents and fellows, clinical psychologists, and psychiatric nurses a comprehensive but concise compilation of research in this area, this reference informs clinical mental health practice as well as policy decisions by articulating the connection between marijuana and mental health, particularly in the United States.

In “a brilliant antidote to all the…false narratives about pot” (American Thinker), an award-winning author and former New York Times reporter reveals the link between teenage marijuana use and mental illness, and a hidden epidemic of violence caused by the drug—facts the media have ignored as the United States rushes to legalize cannabis. Recreational marijuana is now legal in nine states. Advocates argue cannabis can help everyone from veterans to cancer sufferers. But legalization has been built on myths—that marijuana arrests fill prisons; that most doctors want to use cannabis as medicine; that it can somehow stem the opiate epidemic; that it is beneficial for mental health. In this meticulously reported book, Alex Berenson, a former New York Times reporter, explodes those myths, explaining that almost no one is in prison for marijuana; a tiny fraction of doctors write most authorizations for medical marijuana, mostly for people who have already used; and marijuana use is linked to opiate and cocaine use. Most of all, THC—the chemical in marijuana responsible for the drug’s high—can cause psychotic episodes. “Alex Berenson has a reporter’s tenacity, a novelist’s imagination, and an outsider’s knack for asking intemperate questions” (Malcolm Gladwell, The New Yorker), as he ranges from the London institute that is home to the scientists who helped prove the cannabis-psychosis link to the Colorado prison where a man now serves a thirty-year sentence after eating a THC-laced candy bar and killing his wife. He sticks to the facts, and they are devastating. With the US already gripped by one drug epidemic, Tell Your Children is a “well-written treatise” (Publishers Weekly) that “takes a sledgehammer to the promised benefits of marijuana legalization, and cannabis enthusiasts are not going to like it one bit” (Mother Jones).

The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management.

Risk Factors for Psychosis: Paradigms, Mechanisms, and Prevention combines the related, but disparate research endeavors into a single text that considers all risk factors for psychosis, including biological, psychological and environmental factors. The book also introduces the ethics and current treatment evidence that attempts to ameliorate risk or reduce the number of individuals with risk factors developing a psychotic disorder. Finally, the book highlights new research paradigms that will further enhance the field in the future. Psychotic disorders affect more than 50 million people worldwide, creating a devastating effect on lives and causing major financial and emotional impact on families and on society as a whole. The search for risk factors for psychosis has developed rapidly over the past decades, invigorated by changes in the thinking about the malleability and treatability of psychotic disorders. The paradigms for investigating psychosis risk have developed, often in parallel, but there has been no book to date that has summarized and synthesized the current approaches. - Integrates research from biological, psychological and environmental factors into a single resource - Offers insight into at-risk paradigms, biomarkers, and the current state of research on treatment option for psychosis - Presents a holistic and dynamic look at risk syndromes and how they can be measured through neuroimaging, neuropsychology and other methods